GSK PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,605 GBX | -0.62% |
|
-0.62% | +10.67% |
| 06-12 | Moderna's RSV Vaccine Has 'Ample Opportunity' Despite Seasoned Competitors, Oppenheimer Says | MT |
| 06-12 | GSK: licensing agreement with Ochre Bio | CF |
ETFs positioned on GSK plc
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.17% | 11 M€ | +0.83% | - | |
| 3.15% | 21 M€ | +8.21% | - | |
| 2.51% | 7 M€ | +10.58% | - | |
| 1.96% | 3 M€ | +9.95% | - | |
| 0.88% | 6 M€ | -.--% | ||
| 0.83% | 2 M€ | -.--% | - | |
| 0.83% | 2 M€ | +9.19% | - | |
| 0.77% | 251 M€ | +8.30% | ||
| 0.75% | 51 M€ | +8.46% | ||
| 0.55% | 5 M€ | -.--% | - | |
| 0.50% | 252 M€ | +7.39% | ||
| 0.40% | 10 M€ | -3.35% | - | |
| 0.37% | 29 M€ | +8.37% | - | |
| 0.37% | 261 M€ | -.--% | - | |
| 0.37% | 200 M€ | +11.39% | - | |
| 0.37% | 488 M€ | +15.16% | ||
| 0.32% | 7 M€ | +5.82% | - | |
| 0.31% | 35 M€ | +5.63% | - | |
| 0.29% | 749 M€ | +8.81% |
GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Sector
Pharmaceuticals
Calendar
2024-06-17
- Analyst Meeting - Getting Ahead of Cancer
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
16.05
GBP
Average target price
20.36
GBP
Spread / Average Target
+26.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.67% | 83.79B | |
| +48.79% | 780B | |
| +41.76% | 627B | |
| +19.43% | 334B | |
| +7.18% | 296B | |
| +17.60% | 244B | |
| -0.41% | 217B | |
| +11.54% | 214B | |
| +4.53% | 161B | |
| -3.92% | 159B |
- Stock Market
- Equities
- GSK Stock
- Funds and ETFs GSK plc
